Navigating CML Treatment: A Patient-Centered Approach - Episode 4
Beyond T315I mutations: When to Consider Ponatinib or Asciminib in CML Second-Line Treatment
Panelists discuss how when choosing between asciminib and ponatinib for chronic myeloid leukemia treatment, key considerations include the patient’s mutation status, prior tyrosine kinase inhibitor therapy response, cardiovascular risk factors and comorbidities, and the differing safety profiles of the 2 drugs, with ponatinib generally having more cardiovascular concerns but broader mutation coverage vs asciminib’s more favorable tolerability but more specific targeting of BCR::ABL1.
Video content above is prompted by the following:
- What do you consider when making a treatment decision between asciminib and ponatinib?
- What disease-specific factors do you consider?
- What patient factors do you consider?